| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Julien Guiot | Q88816338 |
| P2093 | author name string | Renaud Louis | |
| Monique Henket | |||
| Catherine Moermans | |||
| Jean-Louis Corhay | |||
| P2860 | cites work | A novel human CC chemokine PARC that is most homologous to macrophage-inflammatory protein-1 alpha/LD78 alpha and chemotactic for T lymphocytes, but not for monocytes | Q24318783 |
| Recent advances in understanding idiopathic pulmonary fibrosis | Q26745905 | ||
| Peripheral blood biomarkers in idiopathic pulmonary fibrosis | Q27000707 | ||
| Molecular biomarkers in idiopathic pulmonary fibrosis | Q27025340 | ||
| Heterogeneous gene expression signatures correspond to distinct lung pathologies and biomarkers of disease severity in idiopathic pulmonary fibrosis | Q27316615 | ||
| Diagnosis of idiopathic pulmonary fibrosis: Current issues | Q27687737 | ||
| Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis | Q28240230 | ||
| A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis | Q28240241 | ||
| An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management | Q28308246 | ||
| MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis | Q28472658 | ||
| Periostin promotes fibrosis and predicts progression in patients with idiopathic pulmonary fibrosis | Q30415751 | ||
| Circulating peripheral blood fibrocytes in human fibrotic interstitial lung disease | Q30442380 | ||
| CD28 down-regulation on circulating CD4 T-cells is associated with poor prognoses of patients with idiopathic pulmonary fibrosis | Q33529016 | ||
| C-X-C motif chemokine 13 (CXCL13) is a prognostic biomarker of idiopathic pulmonary fibrosis | Q33901646 | ||
| Incidence and prevalence of idiopathic pulmonary fibrosis | Q33997249 | ||
| MicroRNAs and the regulation of fibrosis | Q34238322 | ||
| Fibulin-1 predicts disease progression in patients with idiopathic pulmonary fibrosis | Q34299791 | ||
| Serum CC-chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis | Q83264263 | ||
| Increased expression of YKL-40, a chitinase-like protein, in serum and lung of patients with idiopathic pulmonary fibrosis | Q83936030 | ||
| Surfactant protein-D predicts survival in patients with idiopathic pulmonary fibrosis | Q84435883 | ||
| Production and activation of matrix metalloproteinase 7 (matrilysin 1) in the lungs of patients with idiopathic pulmonary fibrosis | Q84615570 | ||
| Serum and BALF YKL-40 levels are predictors of survival in idiopathic pulmonary fibrosis | Q85122324 | ||
| Baseline KL-6 predicts increased risk for acute exacerbation of idiopathic pulmonary fibrosis | Q87891339 | ||
| Pirfenidone exerts a suppressive effect on CCL18 expression in U937-derived macrophages partly by inhibiting STAT6 phosphorylation. | Q51359224 | ||
| An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. | Q51612566 | ||
| Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary fibrosis: an analysis from the prospective, multicentre PROFILE study. | Q51650044 | ||
| Global impairment of CD4+CD25+FOXP3+ regulatory T cells in idiopathic pulmonary fibrosis. | Q51738569 | ||
| Prognostic value of circulating KL-6 in idiopathic pulmonary fibrosis. | Q53546521 | ||
| Surfactant protein C mutations are the basis of a significant portion of adult familial pulmonary fibrosis in a dutch cohort. | Q54418482 | ||
| Circulating Fibrocytes Are an Indicator of Poor Prognosis in Idiopathic Pulmonary Fibrosis | Q61892487 | ||
| Soluble intercellular adhesion molecule-1 (ICAM-1) in sera and bronchoalveolar lavage (BAL) fluids of extrinsic allergic alveolitis | Q71730970 | ||
| KL-6: A Serum Marker for Interstitial Pneumonia | Q71956962 | ||
| Surfactant components modulate fibroblast apoptosis and type I collagen and collagenase-1 expression | Q73127485 | ||
| KL-6, a human MUC1 mucin, is chemotactic for human fibroblasts | Q73893704 | ||
| Comparative studies of circulating KL-6, type III procollagen N-terminal peptide and type IV collagen 7S in patients with interstitial pneumonitis and alveolar pneumonia | Q73986520 | ||
| Serum surfactant proteins A and D as prognostic factors in idiopathic pulmonary fibrosis and their relationship to disease extent | Q74316652 | ||
| Serum level of interleukin 8 is elevated in idiopathic pulmonary fibrosis and indicates disease activity | Q74363386 | ||
| Circulating KL-6 predicts the outcome of rapidly progressive idiopathic pulmonary fibrosis | Q77563835 | ||
| CCL18 as an indicator of pulmonary fibrotic activity in idiopathic interstitial pneumonias and systemic sclerosis | Q80238474 | ||
| Cytokine levels in the sera of patients with idiopathic pulmonary fibrosis | Q81374577 | ||
| Periostin, a matrix protein, is a novel biomarker for idiopathic interstitial pneumonias | Q82994146 | ||
| The chitinase and chitinase-like proteins: a review of genetic and functional studies in asthma and immune-mediated diseases | Q34479904 | ||
| Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases. | Q34520692 | ||
| High serum concentrations of surfactant protein A in usual interstitial pneumonia compared with non-specific interstitial pneumonia | Q35535402 | ||
| Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis | Q35558781 | ||
| Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis | Q35683018 | ||
| Raised serum levels of IGFBP-1 and IGFBP-2 in idiopathic pulmonary fibrosis | Q36027009 | ||
| Semaphorin 7A plays a critical role in TGF-beta1-induced pulmonary fibrosis | Q36229334 | ||
| Sputum biomarkers in IPF: Evidence for raised gene expression and protein level of IGFBP-2, IL-8 and MMP-7. | Q36274279 | ||
| Semaphorin 7a+ regulatory T cells are associated with progressive idiopathic pulmonary fibrosis and are implicated in transforming growth factor-β1-induced pulmonary fibrosis | Q36605083 | ||
| Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis | Q36849123 | ||
| Patients with idiopathic pulmonary fibrosis with antibodies to heat shock protein 70 have poor prognoses | Q36917458 | ||
| Serum extracellular vesicular miR-21-5p is a predictor of the prognosis in idiopathic pulmonary fibrosis. | Q37233229 | ||
| Plasma Leptin Is Elevated in Acute Exacerbation of Idiopathic Pulmonary Fibrosis. | Q37239694 | ||
| Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis. | Q37277707 | ||
| Matrix metalloproteinases in respiratory diseases: from pathogenesis to potential clinical implications | Q37438061 | ||
| Metalloproteinases in idiopathic pulmonary fibrosis | Q37893821 | ||
| Biomarkers in idiopathic pulmonary fibrosis | Q38030826 | ||
| PROFILEing idiopathic pulmonary fibrosis: rethinking biomarker discovery. | Q38111258 | ||
| Chronic hypersensitivity pneumonitis in patients diagnosed with idiopathic pulmonary fibrosis: a prospective case-cohort study. | Q38178799 | ||
| Tissue is an issue in the search for biomarkers in idiopathic pulmonary fibrosis | Q38367113 | ||
| Personalized medicine in idiopathic pulmonary fibrosis: facts and promises | Q38541522 | ||
| Plasma Surfactant Protein-D, Matrix Metalloproteinase-7, and Osteopontin Index Distinguishes Idiopathic Pulmonary Fibrosis from Other Idiopathic Interstitial Pneumonias. | Q39791661 | ||
| YKL-40 is elevated in patients with chronic obstructive pulmonary disease and activates alveolar macrophages | Q39938215 | ||
| A vicious circle of alveolar macrophages and fibroblasts perpetuates pulmonary fibrosis via CCL18. | Q40328974 | ||
| KL-6, a human MUC1 mucin, promotes proliferation and survival of lung fibroblasts | Q40351120 | ||
| Peripheral blood mononuclear cell gene expression profiles predict poor outcome in idiopathic pulmonary fibrosis | Q41830012 | ||
| Role of semaphorin 7a signaling in transforming growth factor β1-induced lung fibrosis and scleroderma-related interstitial lung disease | Q42061983 | ||
| CCL18-stimulated upregulation of collagen production in lung fibroblasts requires Sp1 signaling and basal Smad3 activity | Q42481241 | ||
| Significance of serum vascular endothelial growth factor level in patients with idiopathic pulmonary fibrosis | Q43196827 | ||
| Serum surfactant proteins-A and -D as biomarkers in idiopathic pulmonary fibrosis | Q43527848 | ||
| Increased levels of KL-6 and subsequent mortality in patients with interstitial lung diseases | Q43615292 | ||
| Serum lysyl oxidase-like 2 levels and idiopathic pulmonary fibrosis disease progression | Q46359641 | ||
| Usefulness of monitoring the circulating Krebs von den Lungen-6 levels to predict the clinical outcome of patients with advanced nonsmall cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors. | Q46715482 | ||
| Expression of vascular permeability factor/vascular endothelial growth factor in normal rat tissues | Q48309780 | ||
| Circulating intercellular adhesion molecule-1 (ICAM-1) antigen in sera of patients with idiopathic pulmonary fibrosis | Q50174032 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 3 | |
| P921 | main subject | respiratory system | Q7891 |
| pulmonary fibrosis | Q32446 | ||
| biomarker | Q864574 | ||
| idiopathic pulmonary fibrosis | Q2290446 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 273-280 | |
| P577 | publication date | 2017-03-28 | |
| 2017-06-01 | |||
| P1433 | published in | Lung | Q15765075 |
| P1476 | title | Blood Biomarkers in Idiopathic Pulmonary Fibrosis | |
| P478 | volume | 195 |
| Q91777189 | Biomarkers in systemic sclerosis-associated interstitial lung disease: review of the literature |
| Q60912200 | Breath biomarkers in idiopathic pulmonary fibrosis: a systematic review |
| Q48558256 | Clinical experience in idiopathic pulmonary fibrosis: a retrospective study |
| Q90291712 | Comorbidity in idiopathic pulmonary fibrosis - what can biomarkers tell us? |
| Q91708612 | Could airway basal cells be a novel predictor of mortality in IPF? |
| Q93017102 | Exosomal miRNAs in Lung Diseases: From Biologic Function to Therapeutic Targets |
| Q33916589 | Fibrocyte measurement in peripheral blood correlates with number of cultured mature fibrocytes in vitro and is a potential biomarker for interstitial lung disease in Rheumatoid Arthritis. |
| Q92741862 | GDF15 is an epithelial-derived biomarker of idiopathic pulmonary fibrosis |
| Q52673165 | Global Gene Expression Analysis in an in vitro Fibroblast Model of Idiopathic Pulmonary Fibrosis Reveals Potential Role for CXCL14/CXCR4. |
| Q58747855 | Identification of MMP28 as a biomarker for the differential diagnosis of idiopathic pulmonary fibrosis |
| Q46246621 | Identification of the lipid biomarkers from plasma in idiopathic pulmonary fibrosis by Lipidomics |
| Q57170607 | Idiopathic Pulmonary Fibrosis (IPF): An Overview |
| Q50326794 | Idiopathic pulmonary fibrosis: pathogenesis and management. |
| Q89696675 | Matrix Metalloproteinases Retain Soluble FasL-mediated Resistance to Cell Death in Fibrotic-Lung Myofibroblasts |
| Q90080269 | Mucins as a New Frontier in Pulmonary Fibrosis |
| Q90263056 | Prognostic role of blood KL-6 in rheumatoid arthritis-associated interstitial lung disease |
| Q58589241 | Serum AGE/RAGEs as potential biomarker in idiopathic pulmonary fibrosis |
| Q48268746 | Serum metabolic profiling identified a distinct metabolic signature in patients with idiopathic pulmonary fibrosis - a potential biomarker role for LysoPC. |
| Q91655582 | Sputum exosomes: promising biomarkers for idiopathic pulmonary fibrosis |
| Q47282447 | The Lung Microbiome in Idiopathic Pulmonary Fibrosis: A Promising Approach for Targeted Therapies |
| Q47687378 | The interstitial lung disease multidisciplinary meeting: A position statement from the Thoracic Society of Australia and New Zealand and the Lung Foundation Australia. |
Search more.